Why the study?
Does DDAVP infusion improve plasma vWF:Ag, RiCof, and bleeding time in patients with Type I von Willebrand disease?
Population
17 patients (13 kindreds) diagnosed with Type I von Willebrand disease (vWD)
Design
Case_series
Authors
Loading...
DDAVP response may vary by platelet vWF in Type I vWD; hypothesis-generating and should not yet change practice.
Does DDAVP infusion improve plasma vWF:Ag, RiCof, and bleeding time in patients with Type I von Willebrand disease?
Type I von Willebrand disease exhibits heterogeneity, and DDAVP normalizes bleeding time only in a specific subgroup with normal platelet levels of vWF:Ag and RiCof.
Mannucci et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: